Serological Assays for the Detection and Characterization of Influenza Viruses

The Centers for Disease Control and Prevention (CDC) is seeking a contractor to provide serological assays for the detection and characterization of influenza viruses. The contractor will be responsible for testing human sera via hemagglutination inhibition assay and developing a new serology platform that is comparable to hemagglutination inhibition assay. The contract will be for a base period of 12 months, with four optional 12-month periods. The contractor will be required to perform tasks such as sample testing, proficiency panel testing, and assay development. The CDC will provide the contractor with standard operating procedures, proficiency panels, and positive and negative controls. • The contractor will be required to perform HAI serological assays on human samples, with a base level of 6,000 samples per year. • The contractor will be required to develop and validate a new serology assay comparable to HAI. • The contractor will be required to provide a detailed cost proposal, including direct and indirect costs. • The contractor will be required to provide a technical proposal, including a technical approach, management plan, staffing plan, and similar experience. • The contractor will be required to provide a past performance proposal, including information on previous contracts and customer satisfaction.